89bio is developing therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
89bio is developing therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
89bio
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswire89bio Reports Second Quarter 2025 Financial Results and Corporate Updates – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; ea